2024
Modeling delay of age at natural menopause with planned tissue cryopreservation and autologous transplantation
Johnson J, Lawley S, Emerson J, Oktay K. Modeling delay of age at natural menopause with planned tissue cryopreservation and autologous transplantation. American Journal Of Obstetrics And Gynecology 2024, 230: 426.e1-426.e8. PMID: 38184290, DOI: 10.1016/j.ajog.2023.12.037.Peer-Reviewed Original ResearchOvarian tissue cryopreservationTissue cryopreservationFollicle survivalOvarian reserveOvarian agingOvarian cortexOvarian tissue freezingDelay of ageEarly adult agePost transplantationGonadotoxic treatmentHealthy womenFollicle lossNatural menopauseAutologous transplantationMenopauseMost womenTransplantationOvarian tissueCortex removalTransplant techniquesMultiple proceduresAge 25Adult ageTissue harvest
2022
Fertility Preservation in Breast Cancer Patients
Marin L, Turan V, Oktay K. Fertility Preservation in Breast Cancer Patients. 2022, 185-198. DOI: 10.1007/978-3-030-47767-7_14.Peer-Reviewed Original ResearchFertility preservation issuesBreast cancerGonadotropin-releasing hormone agonistNovel chemotherapy regimensSafety of pregnancyFertility preservation techniquesBreast cancer survivorsBreast cancer patientsBreast cancer survivalPremature ovarian insufficiencyBreast cancer treatmentChemotherapy regimensOvarian suppressionPremenopausal womenOvarian reserveHormone agonistCancer survivorsCommon malignancyFertility preservationOvarian functionCancer patientsCancer survivalBRCA mutationsSexual dysfunctionFertility risks
2021
Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data
Turan V, Lambertini M, Lee D, Wang E, Clatot F, Karlan B, Demeestere I, Bang H, Oktay K. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. Journal Of Clinical Oncology 2021, 39: 2016-2024. PMID: 33891474, PMCID: PMC8260903, DOI: 10.1200/jco.20.02880.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataSerum AMH levelsDiminished ovarian reservePatient-level dataAMH levelsOvarian reservePathogenic variantsGermline BRCA pathogenic variantLow serum AMH levelsAnti-Müllerian hormone levelsOral contraceptive pill useLower AMH levelsDecreased ovarian reserveBody mass indexContraceptive pill useBRCA pathogenic variantsEvaluable womenMass indexMean ageHormone levelsBreast cancerAffected womenPill useMeta-AnalysisYoung women
2020
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
Goldfarb S, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, Bang H, Patil S, Dickler M, Oktay K. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Research And Treatment 2020, 185: 165-173. PMID: 32930927, PMCID: PMC7877450, DOI: 10.1007/s10549-020-05933-7.Peer-Reviewed Original ResearchConceptsAnti-Mullerian hormoneOvarian reserveAdjuvant chemotherapyBreast cancerAMH levelsChemotherapy regimensCompletion of ACSerum AMH levelsAdjuvant tamoxifenAMH recoveryChemotherapy groupPrimary diagnosisBaseline ageMethodsOne hundredAMH assessmentRegimensChemotherapyYoung womenTamoxifenSignificant recoveryCancerMixed effects modelsMonthsTreatment effectsWomenIMPACT OF ADJUVANT CHEMOTHERAPY OR TAMOXIFEN ALONE ON THE OVARIAN RESERVE OF YOUNG WOMEN WITH BREAST CANCER: A PROSPECTIVE LONGITUDINAL STUDY
Oktay K, Turan V, Bedoschi G, Taylan E, Bang H, Dickler M, Goldfarb S. IMPACT OF ADJUVANT CHEMOTHERAPY OR TAMOXIFEN ALONE ON THE OVARIAN RESERVE OF YOUNG WOMEN WITH BREAST CANCER: A PROSPECTIVE LONGITUDINAL STUDY. Fertility And Sterility 2020, 114: e531-e532. DOI: 10.1016/j.fertnstert.2020.09.051.Peer-Reviewed Original ResearchUnraveling the mechanisms of chemotherapy-induced damage to human primordial follicle reserve: road to developing therapeutics for fertility preservation and reversing ovarian aging
Szymanska K, Tan X, Oktay K. Unraveling the mechanisms of chemotherapy-induced damage to human primordial follicle reserve: road to developing therapeutics for fertility preservation and reversing ovarian aging. Molecular Human Reproduction 2020, 26: 553-566. PMID: 32514568, PMCID: PMC7411370, DOI: 10.1093/molehr/gaaa043.Peer-Reviewed Original ResearchConceptsPrimordial follicle reserveChemotherapy-induced damageFollicle reserveOvarian reserveChemotherapy-induced lossOvarian reserve depletionApoptotic deathPrimordial follicle oocytesFertility preservationAcute reductionOvarian agingHuman ovaryFollicle activationPrimordial folliclesAcute exposureStromal damageTranslational evidenceChemotherapeutic agentsApoptotic lossFollicle oocytesDNA double-strand breaksDNA DSBsCurrent literatureDeathActivationImpact of breast cancer chemotherapy on ovarian damage and recovery.
Goldfarb S, Bedoschi G, Turan V, Crown A, Abdo N, Dickler M, Oktay K. Impact of breast cancer chemotherapy on ovarian damage and recovery. Journal Of Clinical Oncology 2020, 38: e24059-e24059. DOI: 10.1200/jco.2020.38.15_suppl.e24059.Peer-Reviewed Original ResearchAMH recoveryBreast cancerBaseline AMHOvarian reserveNon-metastatic breast cancerBaseline AMH levelsTime of diagnosisBreast cancer patientsBreast cancer chemotherapyImpact of chemoImportant predictorCancer ptsChemo groupGonadotoxic chemoChemotherapy regimenOvarian damageSerum AMHAMH levelsStudy entryTamoxifen treatmentFertility preservationLow AMHProspective studyCancer patientsFuture fertility
2019
Chapter 30 Autologous Transplantation of Human Ovarian Tissue
Taylan E, Oktay K. Chapter 30 Autologous Transplantation of Human Ovarian Tissue. 2019, 493-500. DOI: 10.1016/b978-0-12-813209-8.00030-3.Peer-Reviewed Original ResearchHuman ovarian tissueOvarian tissueAutologous transplantationFrozen-thawed human ovarian tissueOvarian tissue cryopreservationReproductive-age womenPremature ovarian failureOvarian reserveGonadotoxic therapyAntineoplastic treatmentGonadotoxic treatmentFertility preservationOvarian cortexOvarian failureAge womenReproductive surgeryTissue cryopreservationEndocrine functionPrimordial folliclesPrepubertal ageNononcological diseasesTransplantationTreatmentDiseaseTissue
2016
Embryo Cryopreservation in Breast Cancer Patients
Bedoschi G, Oktay K. Embryo Cryopreservation in Breast Cancer Patients. 2016, 39-52. DOI: 10.1007/978-4-431-55963-4_3.Peer-Reviewed Original ResearchBreast cancer patientsCancer patientsFertility preservationEmbryo cryopreservationAdjuvant systemic chemotherapyFertility preservation techniquesOvarian stimulation protocolsBreast cancer casesOvarian stimulationSystemic chemotherapyOvarian reserveIncident casesAromatase inhibitorsBreast cancerCancer casesStimulation protocolPatientsDonor semenCommon typeWomenFuture reproductive potentialCancerPreservation techniquesAttractive strategySpecial consideration
2014
A prospective longitudinal study of the impact of breast cancer chemotherapy on ovarian reserve: do individuals have differing susceptibilities?
Oktay K, Goldfarb S, Bedoschi G, Quistorff J, Grunblatt E, Cigler T, Moy F, Patil S, Goswami S, Dickler M. A prospective longitudinal study of the impact of breast cancer chemotherapy on ovarian reserve: do individuals have differing susceptibilities? Fertility And Sterility 2014, 102: e151. DOI: 10.1016/j.fertnstert.2014.07.517.Peer-Reviewed Original Research
2013
Fertility preservation options in women with endometriosis.
Bedoschi G, Turan V, Oktay K. Fertility preservation options in women with endometriosis. Minerva Obstetrics And Gynecology 2013, 65: 99-103. PMID: 23598777.Peer-Reviewed Original ResearchConceptsReproductive-age womenSuppressive medical therapyFertility preservation optionsFertility preservation proceduresFertility preservation techniquesLow ovarian reserveNormal ovarian tissuesMore effective treatmentsEndometrioma wallIncidental excisionPelvic painUntreated womenOvarian reserveInfertile womenMedical therapyOvarian endometriomaSevere endometriosisSurgical treatmentAge womenChronic conditionsEndometriosis progressionPreservation optionsEffective treatmentEndometriosisImpaired fertility
2012
Prevention of chemotherapy-induced damage to ovarian reserve by sphingosine-1-phosphate
LI F, Ozkaya E, Akula K, Desutter P, Oktay K. Prevention of chemotherapy-induced damage to ovarian reserve by sphingosine-1-phosphate. Journal Of Clinical Oncology 2012, 30: 1097-1097. DOI: 10.1200/jco.2012.30.15_suppl.1097.Peer-Reviewed Original ResearchFollicle deathOvarian functionApoptotic folliclesOvarian reserveChemotherapy agentsPrimordial folliclesMini-osmotic pumpsOld NOD miceChemotherapy-induced damageAssisted reproduction techniquesSphingosine-1-PhosphateChemotherapy injectionsNOD miceContinuous infusionTotal folliclesPharmacological meansD groupS1P treatmentMouse ovariesPathway inhibitorCytotoxic agentsFolliclesS1PDeathSignificant decrease
2009
Association of BRCA1 mutations with diminished ovarian reserve: A common genetic mechanism for breast/ovarian cancer, and infertility?
Oktay K, Kim J, Barad D, Gleicher N, Babayev S. Association of BRCA1 mutations with diminished ovarian reserve: A common genetic mechanism for breast/ovarian cancer, and infertility? Journal Of Clinical Oncology 2009, 27: 11039-11039. DOI: 10.1200/jco.2009.27.15_suppl.11039.Peer-Reviewed Original ResearchRelative riskOvarian reserveBRCA mutationsBreast cancerFertility preservationHereditary breast-ovarian cancer syndromeOocyte reserveBRCA1 mutationsBreast-ovarian cancer syndromeOvarian stimulation protocolsDiminished ovarian reservePreservation of fertilityPossible higher riskOvarian cancer syndromeNumber of oocytesBreast/ovarian cancerPoor response ratesInfertility historyPoor respondersBC patientsMean ageNon-invasive methodOvarian failureOvarian cancerBRCA2 mutations
2008
Dehydroepiandrosterone (DHEA) reduces miscarriage rates in women with diminished ovarian reserve: a multicenter study
Gleicher N, Ryan E, Weghofer A, Oktay K, Blanco-Mejia S, Barad D. Dehydroepiandrosterone (DHEA) reduces miscarriage rates in women with diminished ovarian reserve: a multicenter study. Fertility And Sterility 2008, 90: s258-s259. DOI: 10.1016/j.fertnstert.2008.07.1225.Peer-Reviewed Original Research
2007
A novel xenograft model to test the ovarian toxicity of chemotherapy agents in women
Oktay K, Oktem O. A novel xenograft model to test the ovarian toxicity of chemotherapy agents in women. Journal Of Clinical Oncology 2007, 25: 19504-19504. DOI: 10.1200/jco.2007.25.18_suppl.19504.Peer-Reviewed Original ResearchXenograft modelFollicle lossClinical trialsChemotherapy agentsHuman ovarian xenograft modelPrimordial follicle countsNovel xenograft modelOvarian xenograft modelOvarian reserveFollicle countMice 12Ovarian toxicityCY injectionGonadotoxic effectsPremenopausal femalesSingle doseHuman ovaryOvarian piecesClinical studiesImmunodeficient miceSingle injectionNew agentsOvarian histologyXenograft vasculatureTUNEL staining
2006
O-287 Ovarian reserve is impaired in cancer patients with normal baseline FSH who previously received chemotherapy as determined by response to controlled ovarian stimulation and anti-mullerian hormone measurements: A controlled study
Azim A, Rauch E, Ravich M, Witkin S, Oktay K. O-287 Ovarian reserve is impaired in cancer patients with normal baseline FSH who previously received chemotherapy as determined by response to controlled ovarian stimulation and anti-mullerian hormone measurements: A controlled study. Fertility And Sterility 2006, 86: s123-s124. DOI: 10.1016/j.fertnstert.2006.07.327.Peer-Reviewed Original ResearchO-227 Impact of breast cancer chemotherapy on ovarian reserve: A prospective analysis by menstrual history and ovarian reserve markers
Reh A, Oktem O, Lostritto K, Oktay K. O-227 Impact of breast cancer chemotherapy on ovarian reserve: A prospective analysis by menstrual history and ovarian reserve markers. Fertility And Sterility 2006, 86: s97-s98. DOI: 10.1016/j.fertnstert.2006.07.259.Peer-Reviewed Original Research